Skip to main content

Table 3 Univariate and multivariate analysis results of overall survival rates

From: Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system

Variables Overall Survival Rates Univariate Analysis Multivariate Analysis
n 2-year 3-year p-value HR (95%CI) p-value
Stage IA 193 79 70 0.0348 - 0.0693
IB + IIA 90 65 50   1.484 (0.968–2.242)  
Histology Adenocarcinoma 184 79 69 0.0689 - 0.5293
SCC 79 69 52   1.151 (0.737–1.772)  
Gender Female 69 86 83 0.0016 - 0.0015
Male 214 71 58   2.393 (1.380–4.418)  
Location Upper and Middle 165 76 65 0.925 - 0.9900
Lower 118 73 62   0.997 (0.660–1.489)  
BED (10) IC (Gy) ≥ 90 264 75 65 0.4428 - 0.6830
< 90 19 68 56   1.145 (0.570–2.083)  
Margins from GTV to PTV (mm) ≥ 10 156 72 63 0.3268 - 0.6307
< 10 123 77 64   0.904 (0.596–1.355)  
  1. BED biologically effective dose, CI confidence interval, GTV gross tumor volume, HR hazard ratio, IC isocenter, OS overall survival, PTV planning target volume, SCC squamous cell carcinoma